E-mail a Wiley Online Library Link

Brian H. Kushner, Shakeel Modak, Ellen M. Basu, Stephen S. Roberts, Kim Kramer and Nai-Kong V. Cheung Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody Cancer 119

Article first published online: 30 APR 2013 | DOI: 10.1002/cncr.28137

Posterior reversible encephalopathy syndrome (PRES) is associated with immunotherapy using antidisialoganglioside (anti-GD2) monoclonal antibody, which is now standard for high-risk neuroblastoma, but has not previously been implicated in PRES. Patients receiving this treatment should be closely monitored for, and undergo immediate treatment or evaluation of, symptoms (eg hypertension or headaches) that may herald PRES.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field